Skip to main content

Specialty Pharmacy

  • Orphan drugs to see growth through 2018, report finds

    NEW YORK — Drug makers could strike big with new treatments for rare diseases, according to a new report by a market research firm.

  • Walgreens Specialty fortifies oncology service with six new oral therapies

    DEERFIELD, Ill. — Walgreens Specialty Pharmacy on Thursday added six medications to its oral oncology cycle management program, in a significant expansion of the comprehensive treatment and support program it provides to benefit patients, physicians and payers, the company announced.

  • FDA approves Pfizer, Protalix drug for Gaucher disease

    NEW YORK — The Food and Drug Administration has approved a new treatment for a rare genetic disorder that affects 10,000 people worldwide.

    Pfizer and Protalix BioTherapeutics announced Wednesday the approval of Elelyso (taliglucerase alfa), an enzyme-replacement therapy for the long-term treatment of Type 1 Gaucher disease.

  • 8th annual Armada Specialty Pharmacy Summit sees 30% boost in attendance

    LAS VEGAS — The 8th annual Armada Specialty Pharmacy Summit officially kicked off here at the Wynn casino resort on Wednesday morning, with early attendance figures showing a 30% increase over 2011, when more than 1,500 executives attended.

  • Reports: Dying woman's plea prompts early release of cancer drug

    NEW YORK — An online plea for help from a mother dying of breast cancer prompted the manufacturer of an experimental drug to release it early, according to published reports.

    In an article posted on its website, CNN told the story of 46-year-old Darlene Gant, a woman with stage-four breast cancer, as she wrote letters to be given to her 11-year-old son on his upcoming birthday, and at future events, such as his high school and college graduations and marriage.

  • FDA approves GlaxoSmithKline's Votrient for soft tissue sarcomas

    PHILADELPHIA — The Food and Drug Administration has approved a drug made by GlaxoSmithKline for certain cancer patients.

  • FDA approves Novartis drug for tumors in patients with rare genetic disease

    EAST HANOVER, N.J. — A drug made by Novartis has received approval from the Food and Drug Administration to treat benign kidney tumors related to tuberous sclerosis complex.

    The FDA approved Afinitor (everolimus) tablets for treating the tumors, known as renal angiomyolipomas, in adults with TSC who don't require surgery. The drug already was approved to treat brain tumors known as subependymal giant cell astrocytoma, or SEGA, in patients with TSC.

  • Vaccines in development could open opportunity for specialty pharmacies

    WHAT IT MEANS AND WHY IT'S IMPORTANT — Since the development of the first smallpox vaccine in 1796, vaccines have saved countless lives around the world and helped to make such deadly scourges as smallpox and polio things of the past.

    (THE NEWS: PhRMA report lists almost 300 vaccines under development. For the full story, click here.)

X
This ad will auto-close in 10 seconds